April 24, 2019
1 min read

Xbrane sets sales goals for ranibizumab biosimilar

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Xbrane Biopharma has begun a phase 3 trial of its lead product Xlucane and announced a sales target for the biosimilar, according to a press release.

Xlucane, a ranibizumab (Lucentis, Novartis/Genentech) biosimilar, is being co-developed and commercialized with Stada Arzneimittel AG, and is expected to bring in revenue during the first quarter of 2022, the release said.

The company has set an annual net sales target of 350 million euros after the product launch.

“We strongly believe in the commercial prospects of Xlucane. There is a great need for more cost-efficient products in the ophthalmic VEGFa inhibitor market and I am confident that Xlucane will be received positively by the ophthalmology community and patients,” Xbrane CEO Martin Åmark said.